These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 1820910)

  • 1. Dissolution kinetics of bezafibrate in two solid forms for oral administration.
    Cadorniga R; Hernanez MT; Negro S; Burgos ML; Molina IT
    Eur J Drug Metab Pharmacokinet; 1991; Spec No 3():371-8. PubMed ID: 1820910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative pharmacokinetics of two oral bezafibrate preparations.
    Cadorniga R; Herrero R; Pastoriza P; Molina IT; Gutierrez JA; Iglesias JJ
    Eur J Drug Metab Pharmacokinet; 1991; Spec No 3():261-7. PubMed ID: 1820889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Study on dissolution in vitro of Zhike Pingchuan sustained-release tablets].
    Li X; Feng Z; Huo W; Li Y; Wang B; Zhu S
    Zhongguo Zhong Yao Za Zhi; 2009 May; 34(10):1216-9. PubMed ID: 19673379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers.
    Wang Y; Lee L; Somma R; Thompson G; Bakhtiar R; Lee J; Rekhi GS; Lau H; Sedek G; Hossain M
    Biopharm Drug Dispos; 2004 Mar; 25(2):91-8. PubMed ID: 14872557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmaceutical availability of gliclazide from selected matrix formulation tablets.
    Hermann TW; Dobrucki R; Piechocki S; Resztak M; Reh R
    Med Sci Monit; 2005 Jun; 11(6):BR181-188. PubMed ID: 15917713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Testing lyoequivalency for three commercially sustained-release tablets containing diltiazem hydrochloride.
    Maswadeh HA; Al-Hanbali OA; Kanaan RA; Shakya AK; Maraqa A
    Acta Pol Pharm; 2010; 67(1):93-7. PubMed ID: 20210085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diclofenac sodium multisource prolonged release tablets--a comparative study on the dissolution profiles.
    Bertocchi P; Antoniella E; Valvo L; Alimonti S; Memoli A
    J Pharm Biomed Anal; 2005 Apr; 37(4):679-85. PubMed ID: 15797788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro dissolution of different brands of griseofulvin tablets.
    Khalafalla N
    Pharmazie; 1980; 35(9):555-8. PubMed ID: 7433509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dissolution parameters for sodium diclofenac-containing hypromellose matrix tablet.
    Mourão SC; da Silva C; Bresolin TM; Serra CH; Porta V
    Int J Pharm; 2010 Feb; 386(1-2):201-7. PubMed ID: 19941944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two- and three-layer tablet drug delivery systems for oral sustained release of soluble and poorly soluble drugs.
    Efentakis M; Naseef H; Vlachou M
    Drug Dev Ind Pharm; 2010 Aug; 36(8):903-16. PubMed ID: 20196641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimization and characterization of a pH-independent extended-release hydrophilic matrix tablet.
    Timmins P; Delargy AM; Howard JR
    Pharm Dev Technol; 1997 Feb; 2(1):25-31. PubMed ID: 9552428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Normal and slow-release formulations of bezafibrate: a comparative pharmacokinetic study in man.
    Gandini R; Assereto R; Castoldi D; Cunietti E; Garanzelli P; Monzani W
    Int J Clin Pharmacol Res; 1987; 7(2):149-55. PubMed ID: 3583496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparison of the pharmacokinetics of a quick-release bezafibrate formulation with a sustained-release formulation. 1. Single-dose administration].
    Vens-Cappell B; Hilgenstock C; Gellert M; Kühle K; Reifferscheid I; Winckler P; Bührens KG
    Arzneimittelforschung; 1993 Mar; 43(3):346-50. PubMed ID: 8489566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Report: in vitro dissolution studies of different brands of sustained release diclofenac sodium matrix tablet available in Bangladesh.
    Abdullah MD; Bepary S; Rouf AS
    Pak J Pharm Sci; 2008 Jan; 21(1):70-7. PubMed ID: 18166523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioavailability of ambroxol sustained release preparations. Part I: In vitro dissolution studies.
    Alighieri T; Avanessian S; Berlini S; Bianchi SG; Deluigi P; Valducci R; Guelen PJ
    Arzneimittelforschung; 1988 Jan; 38(1):92-4. PubMed ID: 3365281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and optimization of the drug release determination of iron from iron prolonged release tablets.
    Kincl M; Bibic R; Veber M; Vrecer F
    Pharmazie; 2003 Apr; 58(4):257-9. PubMed ID: 12749408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparative evaluation using in vitro dissolution tests of various sustained release theophylline preparations].
    Kissné CE
    Acta Pharm Hung; 1990 Nov; 60(5-6):191-6. PubMed ID: 2087990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ethanol effects on drug release from Verapamil Meltrex, an innovative melt extruded formulation.
    Roth W; Setnik B; Zietsch M; Burst A; Breitenbach J; Sellers E; Brennan D
    Int J Pharm; 2009 Feb; 368(1-2):72-5. PubMed ID: 18992310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-amylose carboxymethyl starch matrices for oral sustained drug-release: in vitro and in vivo evaluation.
    Nabais T; Brouillet F; Kyriacos S; Mroueh M; Amores da Silva P; Bataille B; Chebli C; Cartilier L
    Eur J Pharm Biopharm; 2007 Mar; 65(3):371-8. PubMed ID: 17275270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Permeability assessment for solid oral drug formulations based on Caco-2 monolayer in combination with a flow through dissolution cell.
    Motz SA; Schaefer UF; Balbach S; Eichinger T; Lehr CM
    Eur J Pharm Biopharm; 2007 May; 66(2):286-95. PubMed ID: 17156983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.